Nuvalent, Inc. (NASDAQ:NUVL) CEO Sells $2,338,470.00 in Stock

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CEO James Richard Porter sold 27,000 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $86.61, for a total transaction of $2,338,470.00. Following the transaction, the chief executive officer now owns 188,113 shares of the company's stock, valued at $16,292,466.93. This trade represents a 12.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

James Richard Porter also recently made the following trade(s):

• On Tuesday, October 15th, James Richard Porter sold 27,000 shares of Nuvalent stock. The shares were sold at an average price of $102.28, for a total value of $2,761,560.00.

Nuvalent Trading Down 5.3 %

Shares of NASDAQ:NUVL traded down $4.65 on Wednesday, reaching $83.45. 395,984 shares of the company traded hands, compared to its average volume of 434,690. Nuvalent, Inc. has a 52 week low of $61.79 and a 52 week high of $113.51. The business's 50-day simple moving average is $94.31 and its 200 day simple moving average is $87.01. The stock has a market capitalization of $5.93 billion, a P/E ratio of -24.05 and a beta of 1.31.

Nuvalent (NASDAQ:NUVL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.35). During the same period last year, the company earned ($0.59) EPS. Sell-side analysts expect that Nuvalent, Inc. will post -3.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NUVL. JPMorgan Chase & Co. raised their price target on Nuvalent from $100.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, October 4th. Barclays started coverage on shares of Nuvalent in a research report on Thursday, August 29th. They issued an "overweight" rating and a $100.00 price objective on the stock. Guggenheim lifted their target price on shares of Nuvalent from $99.00 to $105.00 and gave the company a "buy" rating in a research report on Monday, September 16th. The Goldman Sachs Group raised shares of Nuvalent to a "strong sell" rating in a report on Monday, September 16th. Finally, UBS Group began coverage on shares of Nuvalent in a research report on Thursday, October 24th. They set a "neutral" rating and a $100.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $112.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quest Partners LLC bought a new position in Nuvalent in the 2nd quarter worth $44,000. Amalgamated Bank increased its position in shares of Nuvalent by 21.8% during the second quarter. Amalgamated Bank now owns 1,105 shares of the company's stock valued at $84,000 after buying an additional 198 shares during the period. Portland Investment Counsel Inc. bought a new position in Nuvalent in the third quarter worth about $205,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Nuvalent by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,147 shares of the company's stock worth $213,000 after buying an additional 382 shares during the period. Finally, Public Employees Retirement Association of Colorado purchased a new stake in Nuvalent in the second quarter worth about $218,000. Institutional investors own 97.26% of the company's stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.